ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Passive Biotech Equities

      iShares Biotechnology ETF

      The iShares Biotechnology ETF (the ¡°Fund¡±) seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector.

      $140.35

      Compare similar ETFs

      Fund Size
      Dividend
      Fees
      Current
      Biotechnology ETF IBB
      Fund Size
      $5.98B
      Dividend
      0.3%
      Fees
      0.44%
      Total Stock Market Index Fund VTSAX
      Fund Size
      $1.7T
      Dividend
      -
      Fees
      -
      Total Stock Market Index Fund VTI
      Fund Size
      $1.7T
      Dividend
      1.2%
      Fees
      0.03%
      500 Index Fund VFIAX
      Fund Size
      $1.49T
      Dividend
      -
      Fees
      -
      500 Index Fund VOO
      Fund Size
      $1.49T
      Dividend
      1.2%
      Fees
      0.03%
      View 1315 similar ETFs →

      Average metrics of all companies in portfolio

      Compare to
      Market
      Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $50.2B
      Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. 0.61 %
      Beta Indicates the relationship between the price performance of a share and the market. 0.699
      P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 25.68
      Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything -61.37
      Profitable Companies 63
      PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 159.25
      Price to Sales Ratio Market cap divided by the revenue in the most recent year. 9.3
      Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 22.55
      Compare to
      Market
      Enterprise Value to EBIT Enterprise Value divided by EBIT 13.12
      Enterprise Value to Revenue Enterprise value divided by revenue 126.41
      Total Debt to Enterprise Value Total debt divided by enterprise value 0.1
      Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. NaN
      Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -3377.63%
      Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -
      Return on Equity Equity divided by market cap. 23.64%
      Return on Assets Indicates a company's profitability in relation to its total assets. 14.08%
      Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -11.33%

      Industries

      Healthcare 82.1%
      Other 10.7%
      Materials 0.8%
      Industrials 0.4%
      N/A 6.1%

      Market cap

      Micro Cap 1%
      Small Cap 8%
      Mid Cap 20%
      Large Cap 71%
      Mega Cap 0%

      262 Investments

      P/E-Ratio
      Total Investment
      Weight
      BlackRock Funds III logo

      BlackRock Funds III

      P/E-Ratio
      n/a
      Total Investment
      $698M
      Weight
      13.2%
      Vertex Pharmaceuticals, Inc. logo

      VRTX - Manufacturing

      Vertex Pharmaceuticals, Inc.

      P/E-Ratio
      27.6
      Total Investment
      $408M
      Weight
      7.7%
      Gilead Sciences, Inc. logo

      GILD - Manufacturing

      Gilead Sciences, Inc.

      P/E-Ratio
      22.3
      Total Investment
      $408M
      Weight
      7.7%
      Amgen, Inc. logo

      AMGN - Manufacturing

      Amgen, Inc.

      P/E-Ratio
      23.4
      Total Investment
      $393M
      Weight
      7.4%
      Regeneron Pharmaceuticals, Inc. logo

      REGN - Manufacturing

      Regeneron Pharmaceuticals, Inc.

      P/E-Ratio
      13.7
      Total Investment
      $338M
      Weight
      6.4%
      Alnylam Pharmaceuticals, Inc. logo

      ALNY - Manufacturing

      Alnylam Pharmaceuticals, Inc.

      P/E-Ratio
      -181.5
      Total Investment
      $252M
      Weight
      4.8%
      IQVIA Holdings, Inc. logo

      IQV - Health Care and Social Assistance

      IQVIA Holdings, Inc.

      P/E-Ratio
      26.5
      Total Investment
      $167M
      Weight
      3.2%
      Mettler-Toledo International, Inc. logo

      MTD - Manufacturing

      Mettler-Toledo International, Inc.

      P/E-Ratio
      32.6
      Total Investment
      $151M
      Weight
      2.9%
      Natera, Inc. logo

      NTRA - Health Care and Social Assistance

      Natera, Inc.

      P/E-Ratio
      -90.6
      Total Investment
      $135M
      Weight
      2.6%
      Argenx SE logo

      ARGX - Manufacturing

      Argenx SE

      P/E-Ratio
      46.3
      Total Investment
      $131M
      Weight
      2.5%
      Waters Corp. logo

      WAT - Manufacturing

      Waters Corp.

      P/E-Ratio
      27.2
      Total Investment
      $128M
      Weight
      2.4%
      Biogen, Inc. logo

      BIIB - Manufacturing

      Biogen, Inc.

      P/E-Ratio
      12.6
      Total Investment
      $114M
      Weight
      2.2%
      Insmed, Inc. logo

      INSM - Manufacturing

      Insmed, Inc.

      P/E-Ratio
      -24.9
      Total Investment
      $111M
      Weight
      2.1%
      BioNTech SE logo

      BNTX - Manufacturing

      BioNTech SE

      P/E-Ratio
      -59.1
      Total Investment
      $98.8M
      Weight
      1.9%
      Illumina, Inc. logo

      ILMN - Manufacturing

      Illumina, Inc.

      P/E-Ratio
      12.6
      Total Investment
      $90.9M
      Weight
      1.7%
      BeOne Medicines Ltd. logo

      BGNE - Manufacturing

      BeOne Medicines Ltd.

      P/E-Ratio
      -14.4
      Total Investment
      $83.7M
      Weight
      1.6%
      Incyte Corp. logo

      INCY - Professional, Scientific, and Technical Services

      Incyte Corp.

      P/E-Ratio
      18.8
      Total Investment
      $80.5M
      Weight
      1.5%
      United Therapeutics Corp. logo

      UTHR - Manufacturing

      United Therapeutics Corp.

      P/E-Ratio
      11.1
      Total Investment
      $78.3M
      Weight
      1.5%
      Neurocrine Biosciences, Inc. logo

      NBIX - Manufacturing

      Neurocrine Biosciences, Inc.

      P/E-Ratio
      39.7
      Total Investment
      $74.3M
      Weight
      1.4%
      Exelixis, Inc. logo

      EXEL - Professional, Scientific, and Technical Services

      Exelixis, Inc.

      P/E-Ratio
      16.9
      Total Investment
      $72.1M
      Weight
      1.4%
      BioMarin Pharmaceutical, Inc. logo

      BMRN - Manufacturing

      BioMarin Pharmaceutical, Inc.

      P/E-Ratio
      17.0
      Total Investment
      $64.4M
      Weight
      1.2%
      Moderna, Inc. logo

      MRNA - Manufacturing

      Moderna, Inc.

      P/E-Ratio
      -3.2
      Total Investment
      $58.5M
      Weight
      1.1%
      Genmab A/S logo

      GMAB - Professional, Scientific, and Technical Services

      Genmab A/S

      P/E-Ratio
      17.4
      Total Investment
      $51.9M
      Weight
      1.0%
      Bio-Techne Corp. logo

      TECH - Manufacturing

      Bio-Techne Corp.

      P/E-Ratio
      65.3
      Total Investment
      $49.4M
      Weight
      0.9%
      Blueprint Medicines Corp. logo

      BPMC - Manufacturing

      Blueprint Medicines Corp.

      P/E-Ratio
      -52.9
      Total Investment
      $49.4M
      Weight
      0.9%
      HoMEÔçÒÒŮѸÀ×